立体定向体部放疗与质子治疗在高危不可手术早期非小细胞肺癌中的2期研究
这项随机2期研究比较立体定向体部放疗(SBRT)与立体定向质子治疗(SBPT)在高危、医学上不可手术的早期非小细胞肺癌中的毒性和疗效。因保险覆盖和SBPT缺乏容积成像导致入组不佳提前终止,仅19例可分析,3年总生存SBRT组27.8% vs SBPT组90%,未观察到4/5级毒性。
要点
- 研究因入组不佳提前终止,无法准确评估疗效和毒性。
- SBPT组3年总生存90%,SBRT组27.8%,但样本量小。
- SBPT组1例发生3级皮肤纤维化,无4/5级毒性。
核心结论
- 因入组不佳提前终止,无法准确评估SBRT与SBPT的疗效和毒性差异。
- 未来研究需考虑两种放疗模式的成熟度(尤其机载成像)和SBPT的保险覆盖。
研究设计与样本
- 随机2期研究,纳入医学上不可手术且具有高危特征(中心型或<5 cm T3肿瘤或孤立肺实质复发)的早期NSCLC患者。
- 患者随机分配至SBRT或SBPT,处方剂量为50 Gy(RBE)分4次,每次12.5 Gy(RBE)。
- SBRT采用三维适形放疗或调强放疗,SBPT采用被动散射,最终19例(SBRT 9例,SBPT 10例)纳入分析。
主要发现
- 中位随访32个月,中位总生存SBRT组28个月,SBPT组未达到。
- 3年总生存率SBRT组27.8%,SBPT组90%。
- 3年局部控制率SBRT组87.5%(8/9),SBPT组90.0%(9/10);3年区域控制率SBRT组47.6%(5/9),SBPT组90%(9/10)。
- SBPT组1例发生3级皮肤纤维化,无4/5级毒性。
关键数值与推荐
- 处方剂量为50 Gy(RBE)分4次,每次12.5 Gy(RBE)。
- 高危特征包括中心型肿瘤、<5 cm的T3肿瘤或孤立肺实质复发。
临床怎么用
- 对于高危、不可手术早期NSCLC,SBRT和SBPT均可考虑,但需注意SBPT缺乏容积成像可能影响精准性。
- 未来开展SBPT研究需确保容积成像技术和保险覆盖以提高入组可行性。
局限性
- 研究因入组不佳提前终止,样本量小(仅19例),无法准确评估疗效和毒性。
- SBPT组缺乏容积成像,可能影响治疗精准性和结果比较。
- 保险覆盖问题限制了患者入组,可能引入选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the feasibility of conducting a randomized study to compare the toxicity and efficacy of stereotactic body radiation therapy (SBRT) versus stereotactic body proton therapy (SBPT) for high-risk, medically inoperable, early-stage non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with medically inoperable NSCLC with high-risk features (centrally located or <5 cm T3 tumor or isolated lung parenchymal recurrences) were randomly assigned to SBRT or SBPT. Radiation dose was 50 Gy(relative biological effectiveness [RBE]) in 4 12.5-Gy(RBE) fractions prescribed to the planning target volume. Stereotactic body radiation therapy was given using 3-dimensional conformal radiation therapy or intensity modulated radiation therapy, and SBPT was given using passive scattering. Consistency in patient setup was ensured with on-board cone beam computed tomography for the SBRT group and with orthogonal X rays for the SBPT group. RESULTS: The study closed early owing to poor accrual, largely because of insurance coverage and lack of volumetric imaging in the SBPT group. Ultimately, 21 patients were enrolled, and 19 patients who received 50 Gy in 4 fractions were included for analysis (9 SBRT, 10 SBPT). At a median follow-up time of 32 months, median overall survival time was 28 months in the SBRT group and not reached in the SBPT group. Three-year overall survival was 27.8% and 90%, 3-year local control was 87.5% (8 of 9) and 90.0% (9 of 10), and 3-year regional control was 47.6% (5 of 9) and 90% (9 of 10) in the SBRT and SBPT groups, respectively. One patient in the SBPT group developed grade 3 skin fibrosis. No patients experienced grade 4/5 toxicity. CONCLUSION: Poor accrual, due to lack of volumetric imaging and insurance coverage for proton therapy, led to early closure of the trial and precluded accurate assessment of efficacy and toxicity. Comparable maturity of 2 radiation therapy modalities, particularly on-board imaging, and better insurance coverage for SBPT should be considered for future studies.
引用
- Nantavithya C, Gomez DR, Wei X, et al. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29680255. doi:10.1016/j.ijrobp.2018.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。